Imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1 decrease the parasite burden...

Area of Science:

• Medicinal Chemistry
• Parasitology
• Pharmacology

Background:

• Current toxoplasmosis treatments have limitations, causing side effects.
• There is a critical need for novel, specific anti-Toxoplasma agents.
• Imidazo[1,2-b]pyridazines show promise by inhibiting TgCDPK1.

Purpose of the Study:

• To develop and evaluate imidazo[1,2-b]pyridazine hydrochloride salts for in vivo toxoplasmosis treatment.
• To assess the efficacy and safety of these compounds in a murine model.

Main Methods:

• Synthesized and characterized imidazo[1,2-b]pyridazine hydrochloride salts (SP230, SP231, SP232).
• Assessed in vitro activity against tachyzoites and TgCDPK1.
• Determined pharmacokinetic profiles and in vivo efficacy in a mouse model of acute toxoplasmosis.
• Monitored hepatic and renal toxicity markers.

Main Results:

• All tested salts maintained in vitro activity against TgCDPK1 and T. gondii tachyzoites.
• Imidazo[1,2-b]pyridazine salts significantly reduced parasite burden (>90%) in spleen and lungs.
• No significant short-term hepatic or renal toxicity was observed.

Conclusions:

• Imidazo[1,2-b]pyridazine salts demonstrate potent in vivo efficacy against acute toxoplasmosis.
• These compounds represent promising candidates for further development.
• Further investigation in congenital toxoplasmosis models is warranted.